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Introduction
Laboratory automation at
Schering-Plough increased productivity
today and foundation for the future
Francis H. Zenie
Zymark Corporation, Zymark Center, Hopkinton, MA 01748, USA
Thefollowing is the introductory presentation to the 1994 ISLAR
meeting held in Boston from 16 to 19 October 1994. The Editor
is again grateful to the organizer, the Zymark Corporation, for
permission to publish the papers in the Managing Laboratory
Automation Session read at ISLAR.
Preface
ISLAR 1994 makes many years of hard work worthwhile
and the future more exciting than ever. When we began
Zymark, we stated our vision in our May 1991 introductory
brochure--Zymark--Dedicated to Increased Productivity in
Chemistry and the Biotechnologies. This statement preceded
conceiving the laboratory robotics idea: ’Perhaps the most
critical element limiting technological progress will
become the availability and utilization of skilled people.
The chemical and biological sciences have traditionally
enjoyed an abundance of trained people, resulting in
many labour intensive practices in their research labora-
tories. At Zymark, we believe it will become evident in
the near future that this abundance is rapidly ending.’
We were correct in anticipating a productivity crisis, but
incorrectly defined the cause. We saw robust and
expanding chemical and pharmaceutical industries des-
perate for skilled people. Today’s productivity crisis,
however, is caused by increasing customer demands,
competition and regulation.
We now have a choice: become depressed by this reality
or challenged to create opportunities within it. Examining
the causes of the productivity crisis, we find that it starts
with us as consumers. We have become far more
demanding consumers and our suppliers must continuously
re-earn our business. Think about purchasing a new house
or car or even small appliance: to compete and earn
business, companies must create more value--better
products and services at lower cost. This means jobs and
work must change. Businesses must re-engineer their
processes and we, as individuals, must become more
valuable by renewing and exanding our skills.
We used to ask whether ’automation eliminates jobs’?
This is the wrong question particularly for high value-
added jobs. Senior executives in large companies are
decisively reducing costs based on their perception of
affordability. Senior managements are often measured by
near-term financial performance and are responsible to
their boards of directors who, in turn, are responsible to
the shareholders. The largest, most powerful shareholders,
are institutions such as pension funds, insurance companies
and mutual funds. But, whose money is it? Ours, and we
demand high returns on our investment.
We cannot predict the future and the right strategies are
not clear. In fact strategies in your industries are changing
and actually diverging. Only after three to five years, we
will learn which managements made the best decisions.
Once senior management adjusts their cost structure, they
challenge middle management: ’find a way to do the
necessary work within these financial constraints’.
I have commented at prior ISLARs about the Changing
role of laboratory management. We have virtually
completed the first phase: the transition from technical
expert to leadership and managerial duties. The next step
is to become champions and leaders for increasing
productivity and effectiveness. And, then, we must renew
our commitment to innovation in order to regain control
of the future and not just respond to it. But, we must do
this while continuing to increase productivity. And
technology, such as laboratory automation, is a tool to
help people become more productive and innovative.
The following is a case history: it describes the 10-year
evolution of laboratory automation at Schering-Plough
which will demonstrate one company’s commitment to
preparation for the future.
Increasing cost containment pressures, worldwide competi-
tion, and government ’health care reform’ initiatives
demand increased productivity throughout today’s pharma-
ceutical industry. To improve the critical analyti-
cal support required for new product development and
ongoing quality control, leading pharmaceutical labora-
tories are re-engineering themselves to become more
productive and to use valuable people more effectively.
New methods and technologies are needed to further
stimulate better laboratory support--fully compliant with
current regulations and at lower cost.
Beginning as early pioneers, Schering-Plough has applied
laboratory automation to dramatically increase their
analytical and quality control productivity. Their early
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vision, commitment to improving productivity, belief in
enriching career development and determined implemen-
tation provide important insights for other organiza-
tions in earlier phases of their laboratory automation
programmes.
Schering-Plough’s beliefs
Schering-Plough, a leading research-based pharma-
ceutical company, has a rich tradition of introducing
innovative products and maintaining a strong R&D
pipeline. Schering’s management recognizes the challenges
ahead and they are committed to investing in R&D and
in increasing the productivity of valuable R&D staff.
’The risks and challenges inherent in today’s worldwide
pharmaceutical business have never been greater.
Conversely, the opportunities for Schering-Plough have
never been more plentiful or full of promise.’
Letter to Shareholders--Schering-Plough Corporation,
1992 Annual Report
’Our strategy for many years has been built upon a
fundamental, commitment to research. Only through
investing in R&D will we discover and develop
tomorrow’s life-saving and life-enhancing pharma-
ceuticals. Only through perpetual innovation will
Schering-Plough continue to grow and prosper.’
Letter to Shareholders--Schering-Plough Corporation,
1993 Annual Report
’The quality ofR&D depends on the quality of the
resources. There are a number of components to
success in the pharmaceutical research process. The
most important is our people. At Schering-Plough, we
hire the best talent in our industry. Then we provide
them with the technical resources they need to do their
best work: the most advanced instrumentation; the
latest computerized, systems; modern lab facilities.
Finally, we spend over $500 million on R&D, and have
just completed a $300 million R&D facility.’
Shering-Plough Research Institute--Employment Ad-
vertisement, New York Times, Sunday, August 29th,
1993.
Laboratory automationmgetting started
Following commercial introduction at the 1982 Pittsburgh
Conference, laboratory robotics became quickly recognized
as a powerful new technology for improving both
laboratory productivity and the reproducibility of analytical
results. Steady progress during the past 12 years has
brought laboratory robotics technology and application
know-how to its current capability and critical role in
improving productivity for leading laboratories.
Not surprisingly, Schering-Plough adopted laboratory
robotics technology early. Beginning in 1983, Schering
Research introduced robotics systems for enzyme assays
and Lowry protein assays. Schering’s Physical and
Analytical Chemistry R&D (PACRD) acquired their first
robotic system in 1984 for tablet assays. Schering Quality
Control began applying robotics in 1986 as part of an
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emerging commitment to lab automation. Automated
tablet dissolution testing was QC’s initial application.
followed by automated metered dose inhaler assay.
Today, Schering-Plough is a major user of a wide range
of laboratory automation technology.
At Schering-Plough, laboratory automation includes
automated sample preparation, automated analysis and
automated data acquisition, processing and analysis. Each
ofthese automation areas contribute important value and,
combined into integrated laboratory automation, further
increases the pay off.
Eugene McGonigle, Schering’s Vice President of Physical
and Analytical Chemistry R&D, in his keynote address
at the 1992 ISLAR described the impact of laboratory
automation on a typical gas chromatographic assay:
’Pre-Seventies: One chemist--5 Samples per Day
Seventies: One Chemist--10 Samples in 11/2 Days
Eighties: One Chemist--30 to 40 Samples per
11/2 Days’.
This modern Automation/Robotics/Computers, it is
possible to generate twice the workload in halfthe time--a
fourfold productivity improvement.
Analytical R&D and quality control functions have
different, yet complimentary, objectives for laboratory
automation. In analytical R&D, laboratory automation
is used to increase productivity and improve sample
turnaround for repetitive analyses supporting drug
development. Analytical R&D must determine when,
during the drug development process, to develop and
utilize automated methods. Automating too early may
not pay back because many projects are cancelled during
early development stages and, for those that proceed,
formulations and analytical methods frequently change.
An equally important goal of analytical R&D is methods
transfer to quality control laboratories for product release
and stability analysis. Analytical R&D, consulting with
the quality control staff, develops and validates manual-
equivalent automated methods for subsequent, high
volume use.
Supporting marketed products, quality control performs
efficient and regulatory compliant analytical methods. In
today’s business environment, QC relies on laboratory
automation to gain productivity by increasing analytical
capacity with limited staff and space, while ensuring
consistent use of validated methods and automating
required documentation.
Physical and analytical chemistry R&D
At Schering-Plough, Physical and Analytical Chemistry
R&D (PACRD) provides analytical support throughout
the pharmaceutical development process. Primary tech-
niques include content uniformity, dissolution and stability
indicating assays.
Pharmaceutical development proceeds in phases and
analytical support is particularly difficult during the early
phases, because:
Many projects are terminated early in the development
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Early clinical trials involve few patients using prelimin-
ary formulations and dosage forms. Very often, each
employ different analytical methods.
Initial formulations are refined and additional strengths
added or modified entirely as the development process
proceeds through later stage, higher volume clinical
trials.
Therefore, while many stability samples require testing,
they are placed under stability at different times, making
it difficult to combine or pool related analyses. The
challenge in analytical R&D becomes when to introduce
automated methods during the development process.
Continuing advancements in automation technology
reduce the effort and time needed to adopt automated
techniques for smaller sample loads and, thereby, enabling
cost-effective automation to be introduced earlier in the
development process. Zymark’s PyTechnology, introduced
in 1986, expanded the use of laboratory robotics at
Schering-Plough. More recent developments, such as
modular robotic workstations and powerful, Windows-
based software with intuitive user interfaces and automatic
sample scheduling are further lowering the barriers to
automation. As the flexibility and ease of implementing
laboratory automation increases, automation can be
introduced earlier in the development process.
Schering’s PACRD carefully evaluates each analysis for
’payback’ return on the resources invested in developing
the automated method. The example in table illustrates
an assessment for a solid dosage form, single component
tablet or capsule assayed by HPLC. This demonstrates
effective use of robotic applications when supported by
people experienced in implementing laboratory automa-
tion technology. The incremental addition of nine days
to program and validate the automation is a small part
ot" the methods development project and the additional
time is easily recovered even with moderate sample work
loads.
Teaming vendor resources and internal laboratory
expertise further facilitates the adoption of laboratory
automation during pharmaceutical development. Internal
laboratory staffs are more familiar with their products,
regulatory and analytical needs and, therefore, internal
expertise often leads to faster implementation and
validation. For example, PACRD has decentralized
internal teams that maintain an inventory of automation
modules, configure systems quickly when needed, program
the application and validate methods. Backing up these
teams is Schering’s R&D Engineering Department which
Table 1.
Days of total
Activity required effort
Develop HPLC system & assay 13
Sample preparation 3
Validate manual method 10
Robotic programming 3
Robotic validation 6
Document methods 5
4O Total
34
7
25
7
15
12
100
provides additional engineering, programming and fabrica-
tion capabilities.
Full service system integration vendors, such as Zymark,
bring proven products, know-how from similar applica-
tions, expertise in lab automation technology, custom
product capabilities and a wide range of software
knowledge including interfacing with other manufacturers
products. Specific project needs determine the best mix
of internal and vendor resources.
A recent project, automating content uniformity of a
metered dose inhalation product, required development
of new robotic modules and substantial empirical opti-
mization of dose recovery approaches. The technically
challenging project progressed slowly until a focused effort
was contributed by the vendor (Zymark), Schering’s
PACRD Staff and Schering’s R&D Engineering.
When asked, ’Hou would you approach a new robotics
application, requiring method development and empirical
optimization, in the future?’, a Schering scientist replied:
’Involve Schering R&D Engineering early.
Share manual procedures with the vendor--identify all
critical issues learned from manual experience.
Maintain open, frequent communication with vendor.
Visit vendor for comprehensive pre-shipment review.
Streamline installation process--prioritize issues and
solve critical issues first.
Schedule timely analytical support to ensure rapid
progress during installation.
Install and test systematically, expect problems and
test subsystems, do not run full protocol until success
is expected.
Assess future quality control needs and objectives’.
Based on our experience at Zymark, we agree’.
Quality control
Supporting a comprehensive line of marketed products
and a flow of new products, rapidly increases the
analytical demands of pharmaceutical quality control.
Established methods must be run as efficiently as possible
so skilled resources have time to resolve problems quickly
and prepare for new products. Schering-Plough’s Quality
Control Department relies on laboratory automation to
increase analytical capacity, ensure excellent reproduci-
bility and provide documentation and audit trails.
From the R&D viewpoint, McGonigle points out [1]:
Methods transfer is a stringent requirement for analytical
research and development laboratories. Our main charter,
once stability has been demonstrated and specifications
developed, is to transfer analytical methods, developed in
our laboratories, to other potential sites who will be
required to use these methods to release new products
and continue marketed product stability programs.
Method transfer requires a strong interface with Quality
Control Staff.
As an early user of laboratory robotics, Schering took
advantage oftechnological advancements such as Zymark’s
PyTechnology for system flexibility, System V controller
for computer compatibilty and AccuTrack positioning for
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Table 2.
1985 1986 1987
P7 Samples
l--I Tests
1989 1990 1991
1988 1989
1992
1990 1991
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N
1992
//////
///
1993
1993 1994E 1995P
Samples Permanent
Year tested lab staff
Number Annual Average tests
of tests samples/staff per sample
1989 15500 79
1990 22200 65
1991 30200 77
1992 32000 76
1993 37000 91
1994 est. 34300
1995 prqj. 30900
190
342
392
421
208 200 5.5
276 500 8.1
324 500 10.5
improved system reliability. They became early adopters
of automated workstations such as Zymark’s BenchMate
and BenchMate Tablet Processing Workstations.
To further ensure success. Schering QC maintains a
strong commitment to training their staff" for laboratory
automation.
Figure illustrates the steady addition of laboratory
automation systems at Schering Quality Control [2].
These systems include robotics systems, automated
workstations, semi-automated dissolution systems and
automated spectrophotometers. This ongoing commitment
has paid-off in ever-increasing productivity.
Figure 2 and table 2 illustrates rapid sample growth
through 1993 with virtually unchanged laboratory staff.
Schering’s total QC staff increased significantly during
this period to support non-laboratory requirements. Now,
with projections oflevel or slightly lower sample workloads,
analytical demands continue to increase as regulatory
compliance requires most tests per sample. Automation,
theretbre, is becoming more critical to support ever
increasing analytical requirements.
As common assays such as content uniformity, composite
Table 3. Analytical testing of metered dose inhalers.
Current testing Proposed testing
Description Description
Identification (IR/HPLC) Identification (IR/HPLC)
Leak test
Water content
Particle size (microscope)
Weight per metered dose
Assay: metered dose
Applied time per batch=
20 h
Leak test
Water content
Particle size (microscope)
Weight per metered dose
Assay: metered dose (Beg. & end)*
Total can assay
Chromatographic impurities
Particle size (cascade impactor)*
Application time per batch
75h
Note: Indicates significant impact if not automated.
assays and dissolution testing are routinely automated,
automation vendors and pharmaceutical laboratories
must continue to develop techniques for newer, more
demanding assays. Table 3 illustrates additional tests
being proposed for inhaler delivered drugs. The projected
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Table 4. Manual versus automated testing--Applied time per batch.
Product Manual Automated*
Time saving
(h per batch)
Annual
time
saving
Inhaler product 12 6 6
Inhaler product 2 12 5 7
Inhaler product 3 12 5 7
Tablet product 16 8 8
Tablet product 2 8 4 4
Tablet product 3 6 3"5 2"5
Total annual time savings
1900
8OO
3OO
1200
1200
150
5500 h
*Note: Time includes system start-up/clean-up and report preparation.
increase in applied time per batch illustrates that more
demanding analytical controls must be met by advanced
automation techniques or significantly higher laboratory
staffing.
In quality control, laboratory automation flexibility is
required for high utilization ofautomated systems in order
to ensure high return on financial investment and efficient
space utilization. Table 4 illustrates how Schering QC
automates both high and low volume tests to accumulate
large annual time savings.
Insights
We are still early in the evolution of laboratory automa-
tion technology, but effectively applied, laboratory
automation pays off. Working together, vendors and users
of laboratory automation can ensure near term payback
and build a foundation for the future. Specific challenges
include:
1. Lower the ’Automation Threshold’. That is, reduce
the effort required to automate new methods so
that automation can be introduced earlier in the
drug development process and be easily applied to
multiple methods in quality control. This requires
every-improving technology and know-how from
automation vendors and knowledge centres within
end-user organizations.
2. Expand laboratory automation capabilities. Identify
critical laboratory automation needs that require new
technology or know-how. Develop these applications
as collaborative projects with shared responsibilities
and investment between vendors, end-users and
internal automation staff.
3. Make automated methods more reliable and rugged.
Payback comes from dependable operation.
’Unified Methods’, made possible by methods transfer
between laboratories, are essential to regulatory compli-
ance with high productivity. Wherever possible, therefore,
laboratories should concurrently develop equivalent
manual and automated methods.
Looking forward
Scherling-Plough continues as an active participant in the
laboratory automation revolution. They have build a solid
base ofsuccessful applications and formed a core of skilled
automation specialists. Senior management also recognizes
the capability and potential of laboratory automation.
Having achieved departmental success, Schering-Plough
is raising their sights to interdepartmental considerations
of methods transfer leading to unified methods. Most
important, Schering now has a foundatidn of people and
technology to meet the ever increasing challenges ahead.
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